Reference is made to the stock exchange release published by Arctic Bioscience
12th December 2025 regarding Board approval of share capital increase related to
the exercise of debt conversion rights and corresponding issuance of new shares
in Arctic Bioscience.
The share capital increase has now been registered with the Norwegian Register
of Business Enterprises. As a result, the new share capital of Arctic Bioscience
has increased from NOK 2 685 934 to NOK 2 695 625,60, divided into 26 956 256
shares, each having a nominal value of NOK 0,10.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Act.
For more information, please contact:
Christer L. Valderhaug
CEO
Phone: +47 920 84 601
E-mail: christer@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.
The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.